A Phase II Study of Fulvestrant...

The Oncologist 2020 / 11

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR‐Positive , HER2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, Wang, Shusen
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Oncologist
DOI:
10.1002/onco.13614
Date:
November, 2020
File:
PDF, 512 KB
2020
Conversion to is in progress
Conversion to is failed